Eli Lilly and Company

Renhua Li

Owen Brendan Wallace

Yanping Xu

Thomas Edward Mabry

Leonard Larry Winneroski, Jr

Nancy June Snyder

Thomas Daniel Aicher

Ashraf Saeed

Alexei Pavlovych Krasutsky

Philip Arthur Hipskind

Charles Howard Mitch

Michael R Myers

Ronald Jay Hinklin

Sajan Joseph

Jefferson Ray McCowan

Jeremy Schulenburg York

Ling Liu

Peter Biagio Anzeveno

Gregory Alan Stephenson

Zhaogen Chen

Marvin M Hansen

Julie Kay Bush

Gary A Hite

James Lee Toth

Hongqi Tian

Christopher Randall Schmid

Tatiana Natali Vetman

Aktham Aburub

Yiqing Feng

Takako Wilson

Aaron David Wrobleski

Stephon Cornell Smith

Jenny Pingqi Dai

Leonard Larry Junior Winneroski

Gary Alan Hite

Junior Leonard Larry Winneroski

Michael Ray Myers

Marvin Martin Hansen

Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.

MET antibody drug conjugates

A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.

4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists

The present invention discloses novel compounds of Formula I: (I) having 11-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11-HSD type 1 activity. 

Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: (I) possessing 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

The present invention discloses novel compounds of Formula I: possessing 11 &#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 &#x3b2;-HSD type 1 activity. 

Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

4-[5-(2-Amino-ethanesulfonyl)-isoquinolin-7-yl]-phenol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt thereof as Akt inhibitors that are antineoplastic and/or antiviral agents as well as compositions comprising these compounds and methods of using these compounds.

Inhibitors of AKT (protein kinase B)

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 Beta-HSD type 1 activity. X-17377

The present invention discloses novel compounds of Formula (I): having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Growing community of inventors

Fishers, IN, United States of America

Renhua Li